The prevalence of diabetes mellitus is rising at an alarmingrate and is projected to more than double by 2030.1 The diseasecurrently afflicts 171 million people worldwide, with 23.6 millionin the United States. The adverse microvascular and macrovascularconsequences of diabetes are well recognized, as is the accompanyingaccelerated rate of atherosclerosis that predisposes patientsto coronary artery disease and to higher rates of myocardialinfarction and death. Treatment strategies that are aimed atreducing these events have embraced both optimal medical therapy(lifestyle intervention, vigilant glycemic control, and aggressivesecondary prevention) and interventional management (catheter-basedand surgical . . . [Full Text of this Article]
Source Information
From the Department of Medicine, State University of New York at Buffalo Schools of Medicine and Public Health, Buffalo (W.E.B.); and Nuffield Department of Surgery, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom (D.P.T.).
This article (10.1056/NEJMe0904090) was published on June 7, 2009, at NEJM.org.
This article has been cited by other articles:
Pfisterer, M. E., Zellweger, M. J., Garratt, K. N., Bailey, S. R., Bertoldi, E. G., Weinert, L. S., Polanczyk, C. A., DeVries, J. H., Brooks, M. M., Chaitman, B. R., Molitch, M. E., the BARI 2D Study Group, , Boden, W. E., Taggart, D. P.
(2009). Therapies for type 2 diabetes and coronary artery disease.. NEJM
361: 1407-1408
[Full Text]